Physiomics PLC Awarded further Bicycle Therapeutics contract
06 Abril 2020 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
06 April 2020
6 April 2020
Physiomics plc
("Physiomics") or (the "Company")
Physiomics awarded further contract by Bicycle Therapeutics
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a further contract of undisclosed value by its
existing client, Bicycle Therapeutics ("Bicycle") (the
"Project").
The Project is an extension of the work the Company completed on
Bicycle's lead programme, BT1718 (currently in a Cancer Research
UK-sponsored Phase I/IIa study), which Physiomics announced on 8
July 2019. Physiomics' role is related to the analysis of clinical
data from this trial and its work on the initial project was
acknowledged in a poster presentation, at the ESMO conference, in
September 2019(1) . The Project is expected to be completed in the
next six months.
Dr Jim Millen, CEO said : "We are delighted to continue to
expand our relationship with Bicycle Therapeutics, which is rapidly
becoming a key high-profile client. It's also pleasing that we are
able to sign new business in the current environment and hope to
see this continue over the course of the rest of this calendar
year."
(1)https://www.bicycletherapeutics.com/wp-content/uploads/ESMO-Sep-2019-FINAL.pdf
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions. The Company's Virtual Tumour(TM)
technology uses computer modelling to predict the effects of cancer
drugs and treatments to improve the success rate of drug discovery
and development projects while reducing time and cost. The
predictive capability of Physiomics' technologies have been
confirmed by over 70 projects, involving over 30 targets and 60
drugs, and has worked with clients such as Merck KGaA, Merck &
Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAPLSELDEEFA
(END) Dow Jones Newswires
April 06, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024